Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 4
1952 12
1953 7
1954 8
1955 12
1956 15
1957 8
1958 22
1959 5
1963 1
1964 5
1965 14
1966 9
1967 28
1968 35
1969 45
1970 69
1971 71
1972 77
1973 91
1974 88
1975 81
1976 74
1977 68
1978 71
1979 86
1980 89
1981 80
1982 70
1983 92
1984 81
1985 112
1986 91
1987 91
1988 74
1989 93
1990 113
1991 87
1992 100
1993 121
1994 140
1995 127
1996 120
1997 125
1998 135
1999 115
2000 156
2001 138
2002 147
2003 170
2004 200
2005 176
2006 191
2007 202
2008 244
2009 247
2010 234
2011 307
2012 311
2013 302
2014 279
2015 281
2016 293
2017 311
2018 335
2019 350
2020 346
2021 291
2022 190
2023 149
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

8,282 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant neoplasm of endocrine gland"
Page 1
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Barroso-Sousa R, et al. JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064. JAMA Oncol. 2018. PMID: 28973656 Free PMC article.
OBJECTIVE: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI regimens. ...RESULTS: Overall, 38 randomized clinical trials comprising 7551 patients were included in this systematic review a …
OBJECTIVE: To compare the incidence and risk of endocrine AEs following treatment with US Food and Drug Administration-approved ICI r …
Oncocrinology.
Kalra S, Priya G, Bhattacharya S, Sahay R. Kalra S, et al. J Pak Med Assoc. 2020 Apr;70(4):757-761. J Pak Med Assoc. 2020. PMID: 32296231 Review.
Oncocrinology is the science which studies the complex bi-directional relationship between cancer and the endocrine system, including pathophysiological links, clinical presentation and the impact of cancer treatment and endocrine therapy. This review describ …
Oncocrinology is the science which studies the complex bi-directional relationship between cancer and the endocrine system, including …
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.
Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. Wirth LJ, et al. Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15. Future Oncol. 2022. PMID: 35969032 Free PMC article.
LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. ...This study is active and currently recruiting new patients. …
LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to ca …
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM; SOFT and TEXT Investigators and International Breast Cancer Study Group. Pagani O, et al. J Clin Oncol. 2020 Apr 20;38(12):1293-1303. doi: 10.1200/JCO.18.01967. Epub 2019 Oct 16. J Clin Oncol. 2020. PMID: 31618131 Free PMC article.
PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for premenopausal women with hormone receptor (HR)-positive breast cancer treated with adjuvant exemestane plus ovarian function suppression (OFS …
PURPOSE: The Tamoxifen and Exemestane Trial (TEXT)/Suppression of Ovarian Function Trial (SOFT) showed superior outcomes for p …
Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM, Snel M, Kapiteijn E. Corssmit EPM, et al. Curr Opin Oncol. 2020 Jan;32(1):20-26. doi: 10.1097/CCO.0000000000000589. Curr Opin Oncol. 2020. PMID: 31599769 Review.
For individual patients, overall survival, progression-free survival, and clinical outcome are difficult to predict. Management of metastasized pheochromocytoma and paraganglioma is challenging. ...
For individual patients, overall survival, progression-free survival, and clinical outcome are difficult to predict. Management of me …
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI. Dralle H, et al. Nat Rev Dis Primers. 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. Nat Rev Dis Primers. 2015. PMID: 27188261 Review.
In thyroid cancer surgery, for instance, injuries to structures outside the thyroid gland, such as the recurrent laryngeal nerve in 2-5% of surgeries or the parathyroid glands in 5-10% of surgeries, negatively affect quality of life more than loss of the expendable …
In thyroid cancer surgery, for instance, injuries to structures outside the thyroid gland, such as the recurrent laryngeal nerve in 2 …
Thyroid Sequelae of Pediatric Cancer Therapy.
Waguespack SG. Waguespack SG. Horm Res Paediatr. 2019;91(2):104-117. doi: 10.1159/000495040. Epub 2018 Dec 12. Horm Res Paediatr. 2019. PMID: 30541010 Review.
Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as 131I-metaiodobenzylgua …
Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfuncti …
Malignant ovarian germ-cell tumours.
Low JJ, Ilancheran A, Ng JS. Low JJ, et al. Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):347-55. doi: 10.1016/j.bpobgyn.2012.01.002. Epub 2012 Feb 1. Best Pract Res Clin Obstet Gynaecol. 2012. PMID: 22301054 Free article. Review.
Malignant ovarian germ-cell tumours account for about 5% of all ovarian malignancies and typically present in the teenage years. ...Studies evaluating ovarian and reproductive capacity after conservative surgery and chemotherapy for malignant ovarian germ-cell tumou …
Malignant ovarian germ-cell tumours account for about 5% of all ovarian malignancies and typically present in the teenage years. ...S …
Endocrine oncology in pregnancy.
Lansdown A, Rees DA. Lansdown A, et al. Best Pract Res Clin Endocrinol Metab. 2011 Dec;25(6):911-26. doi: 10.1016/j.beem.2011.06.011. Best Pract Res Clin Endocrinol Metab. 2011. PMID: 22115166 Review.
Endocrine tumours occur rarely in pregnant women but present clinicians with unique challenges. ...The optimal strategy will depend on the nature and stage of the endocrine tumour, gestational stage, treatments available and patient wishes. ...
Endocrine tumours occur rarely in pregnant women but present clinicians with unique challenges. ...The optimal strategy will depend o …
8,282 results